The neuroscience of sleep: Russell Foster at TEDGlobal 2013

First Friday Book Synopsis

Bob''s blog entries Biotechnology and Biological Sciences Research Council Brasenose College at the University of Oxford James Duncan Davidson Margaret Thatcher: “Sleep is for wimps” Royal Society Sleep is for energy conservation [comma] to save calories Sleep is for restoration [comma] to replenish and repair metabolic processes Sleep: A Very Short Introduction Steven W. Here is an excerpt from an article posted by Thu-Huong Ha at the TED website.

Predicting the Future Workplace Today


Exceptional talent is highly prized and human effort is pushed to its limits through physical and medical biotechnology, creating a “new breed of super-workers.” As the dawn of a new year fast approaches, many people are thinking about what changes are ahead of them for 2018.

Top 25 Companies for Pay and Perks (USA Today)

Chart Your Course

Pharmaceutical and biotechnology make up the second-largest group with three representatives: Genentech, Amgen and Pfizer. The top 25 companies for pay and perks. Casey Kelly-Barton, The Motley Fool. Source: USA Today.

Managing Distraction in the Digital Era

Great Leadership By Dan

Guest post from Amy Blankson: In 2013, the National Center for Biotechnology Information reported that the average attention span of a human has dropped to a mere eight seconds , one second behind that of a goldfish.

John Medina: An interview by Bob Morris

First Friday Book Synopsis

He has spent most of his professional life as a private research consultant, working primarily in the biotechnology and pharmaceutical industries on research related to mental health. John Medina is a developmental molecular biologist focused on the genes involved in human brain development and the genetics of psychiatric disorders.

How To Have Sustainable Success

The Idolbuster

Prior to launching her wellness practice, she worked in the management consulting industry and at one of the leading cancer research biotechnology companies. Self Portrait By Jillian Corinne Via Flickr CC. A guest post by Health Coach Catherine Chen, Ph.D. Do you sometimes fall into this trap?

Why You Should Care About The Revenue Forecast

The Idolbuster

I heard a cautionary tale from “George” the former VP of marketing at a mid-sized biotechnology company about how a bogus forecast helped propagate a disaster. Chapter 9: Paint Your Environment: Part 5. As I argued in the last post , if you want the company to do the right thing, make sure you have a set of numbers to back it up. To fully understand why I think this is critical, lets step back for a moment and look at where a revenue forecast come from.

Which Messages Go Viral and Which Ones Don’t

Harvard Business Review

For example, if you are a biotechnology fund manager who wants to communicate the importance of investing in biotechnology, you may think that your value is in your recent success in investing for shareholders, but if you are a reasonable person, you will likely also have doubts about this. How will they feel about the fact that you have a history of success in biotechnology investing?

A Simple Workaround to Overcome the Bureaucratic Mindset

Tanveer Naseer

Russell is an educational psychologist, author, executive coach and management consultant whose clients include Fortune 500 executives in aerospace, healthcare, pharmaceutical and biotechnology, information technology, telecommunications and oil and gas. The following is a guest post by Russell Bishop.

The Promise and Challenge of Big Data for Pharma

Harvard Business Review

From our unique vantage points at Genentech , a leading biotechnology company with a major data science practice, and The Data Incubator , a data-science education company that places and trains data scientists , we have seen how the pharmaceuticals industry has leveraged big data for some potentially revolutionary advances and the challenges it has faced along the way.

The Reason Silicon Valley Beat Out Boston for VC Dominance

Harvard Business Review

In contrast, New England has increasingly become a hub for ventures in life sciences; the first three-quarters of 2016 saw almost 60% of VC investments in New England go to ventures in biotechnology and medical devices. Despite the East Coast roots of technology entrepreneurship and venture capital (VC), by the 1990s Silicon Valley had gained a major advantage over the Cambridge-Boston area. In 1995 Silicon Valley’s share of all VC investments in the U.S.

A Quiet Revolution in Clean-Energy Finance

Harvard Business Review

Their behavior displays promising parallels to the early days of the biotechnology industry. When biotechnology startups like Genentech began to acquire other startups to retain their edge, pharmaceutical incumbents were forced to enter the acquisition melee to remain competitive. Between 2006 and 2008, more than $1 billion venture-capital dollars were channeled into startups focused on solar, wind and biofuel technologies.

IPO 12

The Limits of 3D Printing

Harvard Business Review

Exciting applications have already been demonstrated across all sectors — from aerospace and medical applications to biotechnology and food production.

7 Charts Show How Political Affiliation Shapes U.S. Boards

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., Are corporate boards as polarized politically as the general population?

Why Women Feel More Stress at Work

Harvard Business Review

In one study, female and male MBA students were paired and asked to negotiate the purported purchase of a biotechnology plant. Everyone in today’s supercharged workplaces experiences stress.

So Many M&A Deals Fail Because Companies Overlook This Simple Strategy

Harvard Business Review

The rationale for this approach is highlighted when you compare, for example, the different approaches to M&A employed by a number of legacy pharmaceutical companies and by some relatively newer players in the biotechnology industry.

Why It’s So Hard to Train Someone to Make an Ethical Decision

Harvard Business Review

Take the decision of Sam Waksal, the former CEO of the emerging biotechnology company ImClone Systems. One of the conundrums of ethical decision making is that many moral decisions that are quite straightforward — even easy — to resolve in a classroom or during training exercises seem far more difficult to successfully resolve when confronted during actual day-to-day decision making.

The Political Issues Board Directors Care Most About

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., With the 2016 U.S. presidential election season upon us, what political issues most concern business leaders?

Give Impact Investing Time and Space to Develop

Harvard Business Review

In impact investing, we need to find a way to place that same premium on social impact by valuing the public good being created – just like we do in early stage R&D in science, IT, health, and biotechnology. Impact investing has captured the world’s imagination.

What You Might Not Know About the Cuban Economy

Harvard Business Review

It could be an ideal location for healthcare organizations, but also for those in applied sciences, biotechnology, and pharmaceuticals. And secondly, the business model for Cuban biotechnology has been laughably bad.

Why Boards Aren’t Dealing with Cyberthreats

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., One of the greatest challenges facing boards today is the one directors feel least prepared for: cybersecurity. Yahoo’s disclosure in December of what could be the largest data breach in history was hardly an isolated incident. Indeed, the Guardian dubbed 2016 the “year of the hack,” and cyberthreats are increasingly common across all sectors.

Joining Boards: It's Not Just Who You Know That Matters

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., For many, a corporate directorship is a career capstone. But attaining one is far from easy.

New Research: Where the Talent Wars Are Hottest

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g.,

50 Laboratories of Opportunity

Harvard Business Review

Is it possible that local funding could help bolster tourism in Florida, biotechnology in California, publishing in New York, and agriculture in Iowa? One thing that the Chinese do quite well — and that the U.S. could learn from — is to test policy proposals before rolling them out nationally. A new approach is often tried out first in several cities or provinces to make sure it has the intended effect, and to check for unintended consequences.

Information Technology's Dangerous Trend in Africa

Harvard Business Review

For the past few decades, emerging technologies such as biotechnology, microelectronics, information technology and communications technologies have become central to the socioeconomic development of nations. These technologies improve productivity and facilitate better living standards when they penetrate into societies.

Who's Really Responsible for P&G's Succession Problems?

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., People will continue to debate Procter & Gamble''s move to replace CEO Bob McDonald with his immediate predecessor A.G.

Talent Management: Boards Give Their Companies an "F"

Harvard Business Review

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., What is top of mind for corporate boards worldwide?

Taxpayers Helped Apple, but Apple Won't Help Them

Harvard Business Review

It is not by accident that the National Institutes of Health spends $31 billion a year on supporting innovation in biotechnology and pharmacology. Over the years. taxpayers have been very good to Apple.

Don’t Judge the Economy by the Number of Start-Ups

Harvard Business Review

More new businesses are better for society, right? That’s a common assumption. For instance, take this recent Washington Post piece , headlined, “More businesses are closing than starting. Can Congress help turn that around?” Sounds ominous at first. But wait a minute – is starting more new businesses always a good thing?

Teams Solve Problems Faster When They’re More Cognitively Diverse

Harvard Business Review

We worked with a startup biotechnology company. Looking at the executive teams we work with as consultants and those we teach in the classroom, increased diversity of gender, ethnicity, and age is apparent. Over recent decades the rightful endeavor to achieve a more representative workforce has had an impact. Of course, there is a ways to go, but progress has been made.

The Industries Plagued by the Most Uncertainty

Harvard Business Review

For example, a wide variety of clean technologies (including wind, solar, and hydrogen) are vying to power vehicles and cities at the same time that a wide variety of medical technologies (chemical, biotechnological, genomic, and robotic) are being developed to treat diseases.

Innovative Companies Get Their Best Ideas from Academic Research — Here’s How They Do It

Harvard Business Review

In virtually every advanced field, whether it’s information technology, biotechnology, agriculture, or renewable energy, America holds a leading position. vincent tsui FOR HBR. Since World War II, the U.S. has been an innovation superpower.

Think Global, Not Emerging Markets, Century

Harvard Business Review

Another CEO of a fast-growing biotechnology venture, a Chinese-American entrepreneur, added that he wanted his company to be perceived as American rather than as Chinese. Nokia's recent burning platform travails serve as an object lesson to companies trying to navigate a rapidly-changing global economy. As multinational corporations pursue opportunities in emerging markets, they're bound to stumble if they overlook the developed economies, and vice versa.

How We Built a New Company Culture

Harvard Business Review

I learned this while leading a turnaround of NPS Pharmaceuticals , a biotechnology company that now specializes in creating treatments for rare diseases. Too often, any thought of changing a culture, never mind rebuilding it, seems like a Sisyphean task; the weight of the status quo ultimately rolls back and crushes such efforts. To save the 20-year-old company, I had to get it operating like a start-up.

Should Big Companies Give Up on Innovation?

Harvard Business Review

Start-up companies tend to cluster in industries favored by venture capitalists (like biotechnology or information technology) or ones where there are relatively low barriers to entry (like restaurants). “Why bother?”. It’s a common question thrown at me by entrepreneurs, venture capitalists, or the more cynically minded corporate leaders.

Why Mexico’s Economy Doesn’t Depend on the Next U.S. President

Harvard Business Review

Intense biotechnology research and development activities at some of the country’s universities (and their research farms) have raised the complexity and level of the industry’s outputs. The Mexican peso initially fell 13% in trading after Republican Donald Trump won the U.S. presidency in a surprise result over Democratic nominee Hillary Clinton. It was the biggest drop for the currency since an economic crisis in 1994.

Greenfeld’s “The Subprimes” and the Way Fiction Predicts the Present

Harvard Business Review

Mary Shelley told us nothing about the future of biotechnology, but the popularity and plausibility of Frankenstein: The Modern Prometheus tells us a lot about 1818’s fears and aspirations for technology and its relation to society. NASA/ESA.

When a Product Fails, Find a New Direction

Harvard Business Review

Cephalon's IPO was in 1991, part of the second wave of biotechnology companies to sell shares to the public. Your company has just developed an amazing new product. Years of development, energy, and, of course, money have gone into it. Hype and excitement behind the launch pushes it into high gear. But it falls apart at the seams at the last moment, leaving your company on the brink of disaster. What do you do next?

Predictive Medicine Depends on Analytics

Harvard Business Review

That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. Regression models, Monte Carlo simulations, and other methods for predicting what’s around the corner have been in use for decades.

The Growing Conflict-of-Interest Problem in the U.S. Congress

Harvard Business Review

million for stock in drug device companies in 2015 alone (the numbers are estimates, which is all that is legally required), but Peters is a three-time winner of the Biotechnology Innovation Organization legislator of the year award, the only lawmaker so honored, and is noted for leading opposition to the Innovation Act , legislation that pharmaceutical companies opposed because it imposed new restrictions on patent-infringement lawsuits.